SP-420 / AbFero 
Welcome,         Profile    Billing    Logout  
 12 Diseases   1 Trial   1 Trial   11 News 
  • ||||||||||  SP-420 / AbFero
    Trial completion date, Trial suspension, Trial primary completion date:  Safety of SP-420 in the Treatment of Transfusional Iron Overload (clinicaltrials.gov) -  Dec 15, 2023   
    P1,  N=28, Suspended, 
    Translation of this new, user-friendly therapeutic can significantly benefit veterans and civilians. Trial completion date: Aug 2024 --> Aug 2025 | Recruiting --> Suspended | Trial primary completion date: Aug 2023 --> Dec 2024
  • ||||||||||  SP-420 / AbFero
    Enrollment open, Trial initiation date:  A Trial Testing SP-420 in Subjects With Transfusion-dependent ?-thalassemia (clinicaltrials.gov) -  Oct 23, 2023   
    P2,  N=90, Recruiting, 
    Achievement of these goals will provide innovative, non-invasive, and patient-centered technologies and treatments that will greatly facilitate the treatment of patients with SCI. Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Sep 2023
  • ||||||||||  SP-420 / AbFero
    Trial completion date, Trial primary completion date:  Safety of SP-420 in the Treatment of Transfusional Iron Overload (clinicaltrials.gov) -  Aug 29, 2022   
    P1,  N=28, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Sep 2023 Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2023 --> Aug 2023
  • ||||||||||  SP-420 / AbFero
    Journal:  How does a small molecule bind at a cryptic binding site? (Pubmed Central) -  Apr 13, 2022   
    To this end, we have conducted unbiased, all-atom MD simulations of the binding of four small-molecule inhibitors (SP4206 and three SP4206 analogs) to interleukin 2 (IL2)-which performs its function by forming a PPI with its receptor-without incorporating any prior structural information about the ligands' binding...Binding of the small molecule stabilized the IL2 binding groove, which when the small molecule was not bound emerged only transiently and incompletely. Moreover, free energy perturbation (FEP) calculations successfully distinguished between the native and non-native IL2-small-molecule binding poses found in the simulations, suggesting that binding simulations in combination with FEP may provide an effective tool for identifying cryptic binding sites and determining the binding poses of small molecules designed to disrupt PPI interfaces by binding to such sites.
  • ||||||||||  SP-420 / AbFero
    Enrollment open:  Safety of SP-420 in the Treatment of Transfusional Iron Overload (clinicaltrials.gov) -  Jun 25, 2021   
    P1,  N=28, Recruiting, 
    Moreover, free energy perturbation (FEP) calculations successfully distinguished between the native and non-native IL2-small-molecule binding poses found in the simulations, suggesting that binding simulations in combination with FEP may provide an effective tool for identifying cryptic binding sites and determining the binding poses of small molecules designed to disrupt PPI interfaces by binding to such sites. Not yet recruiting --> Recruiting
  • ||||||||||  SP-420 / AbFero
    Trial completion date, Trial primary completion date:  SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias (clinicaltrials.gov) -  Feb 26, 2020   
    P2,  N=74, Not yet recruiting, 
    N=74 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  SP-420 / AbFero
    Clinical Trial,Phase I, Journal:  Safety and Pharmacokinetics of the Oral Iron Chelator SP-420 in β-thalassemia. (Pubmed Central) -  Nov 30, 2017   
    Based on current dose administration, the renal adverse events observed outweighed the possible benefits from chelation therapy. However, additional studies assessing efficacy and safety of lower doses or less frequent dosing of SP-420 over longer durations with close monitoring would be necessary to better explain the findings of our study and characterize the safety of the study drug.
  • ||||||||||  SP-420 / AbFero
    Trial termination:  Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With ?-Thalassemia (clinicaltrials.gov) -  Sep 29, 2015   
    P1,  N=24, Terminated, 
    However, additional studies assessing efficacy and safety of lower doses or less frequent dosing of SP-420 over longer durations with close monitoring would be necessary to better explain the findings of our study and characterize the safety of the study drug. Active, not recruiting --> Terminated; Changes in renal function parameters.